MolDX: NRAS Genetic Testing

Coverage is limited to somatic NRAS mutation testing on tumor tissue for patients with metastatic colorectal cancer per NCCN (v2.2016) to guide anti‑EGFR therapy decisions; patients with NRAS mutations should not receive cetuximab or panitumumab. All other NRAS testing — including testing for metastatic melanoma, other non‑colorectal tumors, and germline NRAS testing for Noonan syndrome — is considered non‑covered due to insufficient evidence of clinical utility.

"Cover somatic NRAS mutation testing performed on tumor tissue for patients with metastatic colorectal cancer (mCRC) per NCCN Guidelines (Version 2."

Sign up to see full coverage criteria, indications, and limitations.